Citius Oncology Inc. (CTOR)

NasdaqCM: CTOR · 실시간 가격 · USD

0.74

-0.18 (-19.57%)

종가 기준: Aug 19, 2026, 1:06 PM

-19.57% (1D)

매수호가	0.54
시가총액	82.27M
매출 (ttm)	5.61M
순이익 (ttm)	-42.51M
베타	3.49
EPS (ttm)	-0.48
P/E (ttm)	n/a
선행 P/E	n/a
P/B (ttm)	2.05
P/S (ttm)	14.66
Earnings Date	n/a

매도호가	0.98
거래량	274,784
평균 거래량 (20일)	80,365
시가	0.77
전일 종가	0.92
일중 범위	0.70 - 0.78
52주 범위	0.49 - 2.25
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

CTOR 소개

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc....

섹터 Healthcare

IPO 일자 Dec 8, 2022

직원 수 n/a

상장 거래소 NasdaqCM

티커 CTOR

웹사이트 https://citiusonc.com/overview/default.aspx

전체 기업 정보

재무 실적

2025년 Citius Oncology의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -24.76M로, 17.08% 증가했습니다.

재무제표

어닝 서프라이즈

Citius Oncology가 Aug 14, 2026에 분기 실적을 발표했습니다:

매출 $1.67M 예상치 하회 $0, 및 Infinity% 전년 대비 성장.

EPS -0.08 예상치 하회 -0.01, 및 0.00% 전년 대비 성장.

뉴스

2일 전 · InvestorsHub

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Citius Oncology Inc. (NASDAQ:CTOR) shares fell 10.

2개월 전 · Insider Monkey

Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?

With an upside potential of 843.40%, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts. On May 18, H.C. Wainwright analyst Sway...

3개월 전 · Pharmaceutical Technology

Citius raises $36.5m for Lymphir commercialisation

The capital includes a $25m term loan and a warrant exercise agreement expected to yield $11.5m.

4개월 전 · Simply Wall St.

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR)

Citius Oncology, Inc. ( NASDAQ:CTOR ) is possibly approaching a major achievement in its business, so we would like to...

5개월 전 · Insider Monkey

Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius Pharmaceuticals officially transitioned into a revenue-generating company following...

2 페이지 중 1

Citius Oncology Inc. (CTOR)